Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
BioMarin (BMRN) and Ascendis (ASND) settled global patent disputes over Yuviwel. Ascendis will pay BioMarin royalties: 20% in the U.S. and 18% in the EU, Brazil, and South Korea until 2030. Ascendis also received a license to BioMarin's Yuviwel patents. Both companies will dismiss related lawsuits. Ascendis expects 500M euros in 2026 operating cash flow and 5B euros in 2030 revenue.
How this was made
The 30-second read
Why it matters
Legal risk removal and new royalty streams may improve earnings forecasts for BioMarin and shape cost structure for Ascendis.
Market read
First‑report settlement with material royalty terms; relevant for traders in biotech and rare‑disease space.
What to watch
Future regulatory approvals and reimbursement rates for Yuviwel could alter the financial impact.
Background
The settlement resolves multiple ITC and court disputes, allowing both companies to focus on commercialization.
Ticker impact
BioMarin secured a 20% U.S. royalty and an 18% EU/BR/KR royalty from Ascendis, ending global patent disputes.
Potential upside as royalty stream adds margin; monitor for post‑settlement earnings guidance.
Settlement removes litigation risk and creates a new revenue stream, likely viewed favorably by investors.
Ascendis agreed to pay royalties to BioMarin and obtained a full license for BioMarin patents on Yuviwel.
Shares may face slight pressure due to royalty outflow; long‑term upside if sales accelerate.
The deal balances cost with secured rights, creating mixed short‑term sentiment.
Market effects
Sets precedent for royalty settlements in rare‑disease biotech sector.
May influence European and Asian biotech valuations due to cross‑border licensing.
Highlights growing collaboration between US and European biotech firms.
Counterpoint
Royalty payments could erode Ascendis margins, outweighing benefits of the license.
Key entities
- CompanyBioMarin Pharmaceutical Inc.
US biotech firm developing treatments for rare diseases.
- CompanyAscendis Pharma A/S
Danish biotech focused on peptide therapeutics.
